SEE NEW EXPERT VIDEO SERIES ON MANAGING BIOBURDEN
PuraPlyAM
PuraPlyXT

Native, cross-linked extracellular matrix scaffold + sustained antimicrobial effectiveness within the product to support wound healing and aid in granulation tissue formation.

REAL-WORLD STUDY: PURAPLY AM SUPPORTED HEALING IN LARGE, DIFFICULT-TO-HEAL WOUNDS

The first prospective, large (N=307), multicenter (28 sites) cohort study of PuraPly AM showed that 86% of all PuraPly AM-treated wounds demonstrated improvement in the wound bed condition.1

TAKE CONTROL BEFORE BIOFILM RE-FORMS. USE PURAPLY®AM & PURAPLY®XT

Bioburden management with PuraPly®AM and PuraPly®XT helps you move wounds out of the inflammatory phase.

WHY PURAPLY®AM & PURAPLY®XT 

PuraPly AM and PuraPly XT

READY TO TAKE CONTROL OF 
THE HEALING ENVIRONMENT?

Talk to an Organogenesis Tissue Regeneration Specialist about PuraPly®AM and PuraPly®XT

Contact us

CONFIRMATION
OF CONTROL

Examine the scientific and real-world studies that demonstrate the effectiveness of PuraPly®AM and PuraPly®XT

SCIENTIFIC EVIDENCE 
REAL-WORLD EVIDENCE 
Components that make up the Organogenesis Circle of Care program

Organogenesis' Circle of Care is a comprehensive program that provides the highest-quality customer service and reimbursement support. Our wide range of expertise includes:

VIEW ALL SERVICES 

Please refer to the PuraPly AM Instructions for Use and PuraPly XT Instructions for Use for complete prescribing information.

REFERENCES:

  1. Bain MA, et al. J Comp Eff Res. 2020;9(10):691-703. doi:10.2217/cer-2020-0058
  2. Koullias GJ. Wounds. 2021;33(1):20-27.
  3. Hübner NO, et al. Skin Pharmacol Physiol. 2010;23(1 suppl):17-27.
  4. Oropallo AR. Plast Reconstr Surg Glob Open. 2019;7(1):e2047.
  5. Lintzeris D, et al. Wounds. 2018;30(3):72-78.
  6. Data on file. PDR-0001. Organogenesis Inc.
  7. Davis SC, et al. Int Wound J. 2021. Epub ahead of print. doi:10.1111/iwj.13600